Cargando…

Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody

BACKGROUND: In the presence of arterial stenosis, collateral artery growth (arteriogenesis) can alleviate ischemia and preserve tissue function. In patients with poorly developed collateral arteries, Gal‐2 (galectin 2) expression is increased. In vivo administration of Gal‐2 inhibits arteriogenesis....

Descripción completa

Detalles Bibliográficos
Autores principales: Hollander, Maurits R., Jansen, Matthijs F., Hopman, Luuk H. G. A., Dolk, Edward, van de Ven, Peter M., Knaapen, Paul, Horrevoets, Anton J., Lutgens, Esther, van Royen, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818022/
https://www.ncbi.nlm.nih.gov/pubmed/31594443
http://dx.doi.org/10.1161/JAHA.119.012806
_version_ 1783463545839550464
author Hollander, Maurits R.
Jansen, Matthijs F.
Hopman, Luuk H. G. A.
Dolk, Edward
van de Ven, Peter M.
Knaapen, Paul
Horrevoets, Anton J.
Lutgens, Esther
van Royen, Niels
author_facet Hollander, Maurits R.
Jansen, Matthijs F.
Hopman, Luuk H. G. A.
Dolk, Edward
van de Ven, Peter M.
Knaapen, Paul
Horrevoets, Anton J.
Lutgens, Esther
van Royen, Niels
author_sort Hollander, Maurits R.
collection PubMed
description BACKGROUND: In the presence of arterial stenosis, collateral artery growth (arteriogenesis) can alleviate ischemia and preserve tissue function. In patients with poorly developed collateral arteries, Gal‐2 (galectin 2) expression is increased. In vivo administration of Gal‐2 inhibits arteriogenesis. Blocking of Gal‐2 potentially stimulates arteriogenesis. This study aims to investigate the effect of Gal‐2 inhibition on arteriogenesis and macrophage polarization using specific single‐domain antibodies. METHODS AND RESULTS: Llamas were immunized with Gal‐2 to develop anti–Gal‐2 antibodies. Binding of Gal‐2 to monocytes and binding inhibition of antibodies were quantified. To test arteriogenesis in vivo, Western diet‐fed LDLR.(low‐density lipoprotein receptor)–null Leiden mice underwent femoral artery ligation and received treatment with llama antibodies 2H8 or 2C10 or with vehicle. Perfusion restoration was measured with laser Doppler imaging. In the hind limb, arterioles and macrophage subtypes were characterized by histology, together with aortic atherosclerosis. Llama‐derived antibodies 2H8 and 2C10 strongly inhibited the binding of Gal‐2 to monocytes (93% and 99%, respectively). Treatment with these antibodies significantly increased perfusion restoration at 14 days (relative to sham, vehicle: 41.3±2.7%; 2H8: 53.1±3.4%, P=0.016; 2C10: 52.0±3.8%, P=0.049). In mice treated with 2H8 or 2C10, the mean arteriolar diameter was larger compared with control (vehicle: 17.25±4.97 μm; 2H8: 17.71±5.01 μm; 2C10: 17.84±4.98 μm; P<0.001). Perivascular macrophages showed a higher fraction of the M2 phenotype in both antibody‐treated animals (vehicle: 0.49±0.24; 2H8: 0.73±0.15, P=0.007; 2C10: 0.75±0.18, P=0.006). In vitro antibody treatment decreased the expression of M1‐associated cytokines compared with control (P<0.05 for each). Atherosclerotic lesion size was comparable between groups (overall P=0.59). CONCLUSIONS: Inhibition of Gal‐2 induces a proarteriogenic M2 phenotype in macrophages, improves collateral artery growth, and increases perfusion restoration in a murine hind limb model.
format Online
Article
Text
id pubmed-6818022
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68180222019-11-04 Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody Hollander, Maurits R. Jansen, Matthijs F. Hopman, Luuk H. G. A. Dolk, Edward van de Ven, Peter M. Knaapen, Paul Horrevoets, Anton J. Lutgens, Esther van Royen, Niels J Am Heart Assoc Original Research BACKGROUND: In the presence of arterial stenosis, collateral artery growth (arteriogenesis) can alleviate ischemia and preserve tissue function. In patients with poorly developed collateral arteries, Gal‐2 (galectin 2) expression is increased. In vivo administration of Gal‐2 inhibits arteriogenesis. Blocking of Gal‐2 potentially stimulates arteriogenesis. This study aims to investigate the effect of Gal‐2 inhibition on arteriogenesis and macrophage polarization using specific single‐domain antibodies. METHODS AND RESULTS: Llamas were immunized with Gal‐2 to develop anti–Gal‐2 antibodies. Binding of Gal‐2 to monocytes and binding inhibition of antibodies were quantified. To test arteriogenesis in vivo, Western diet‐fed LDLR.(low‐density lipoprotein receptor)–null Leiden mice underwent femoral artery ligation and received treatment with llama antibodies 2H8 or 2C10 or with vehicle. Perfusion restoration was measured with laser Doppler imaging. In the hind limb, arterioles and macrophage subtypes were characterized by histology, together with aortic atherosclerosis. Llama‐derived antibodies 2H8 and 2C10 strongly inhibited the binding of Gal‐2 to monocytes (93% and 99%, respectively). Treatment with these antibodies significantly increased perfusion restoration at 14 days (relative to sham, vehicle: 41.3±2.7%; 2H8: 53.1±3.4%, P=0.016; 2C10: 52.0±3.8%, P=0.049). In mice treated with 2H8 or 2C10, the mean arteriolar diameter was larger compared with control (vehicle: 17.25±4.97 μm; 2H8: 17.71±5.01 μm; 2C10: 17.84±4.98 μm; P<0.001). Perivascular macrophages showed a higher fraction of the M2 phenotype in both antibody‐treated animals (vehicle: 0.49±0.24; 2H8: 0.73±0.15, P=0.007; 2C10: 0.75±0.18, P=0.006). In vitro antibody treatment decreased the expression of M1‐associated cytokines compared with control (P<0.05 for each). Atherosclerotic lesion size was comparable between groups (overall P=0.59). CONCLUSIONS: Inhibition of Gal‐2 induces a proarteriogenic M2 phenotype in macrophages, improves collateral artery growth, and increases perfusion restoration in a murine hind limb model. John Wiley and Sons Inc. 2019-10-09 /pmc/articles/PMC6818022/ /pubmed/31594443 http://dx.doi.org/10.1161/JAHA.119.012806 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Hollander, Maurits R.
Jansen, Matthijs F.
Hopman, Luuk H. G. A.
Dolk, Edward
van de Ven, Peter M.
Knaapen, Paul
Horrevoets, Anton J.
Lutgens, Esther
van Royen, Niels
Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody
title Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody
title_full Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody
title_fullStr Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody
title_full_unstemmed Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody
title_short Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single‐Domain Llama‐Derived Antibody
title_sort stimulation of collateral vessel growth by inhibition of galectin 2 in mice using a single‐domain llama‐derived antibody
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818022/
https://www.ncbi.nlm.nih.gov/pubmed/31594443
http://dx.doi.org/10.1161/JAHA.119.012806
work_keys_str_mv AT hollandermauritsr stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT jansenmatthijsf stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT hopmanluukhga stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT dolkedward stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT vandevenpeterm stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT knaapenpaul stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT horrevoetsantonj stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT lutgensesther stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody
AT vanroyenniels stimulationofcollateralvesselgrowthbyinhibitionofgalectin2inmiceusingasingledomainllamaderivedantibody